Swiss audit reveals 743 million franc scandal in pharmaceutical discounts

An estimated 743 million Swiss francs in rebates and material benefits were provided by the pharmaceutical industry to Swiss medical practices, pharmacies, and hospitals in 2024, according to the Swiss Federal Audit Office (CDF). This staggering figure represents about 8% of the annual drug market cost for mandatory health insurance.

The audit reveals a significant lack of transparency, as only 88 million francs of these benefits were reportedly passed on to insurers or patients. Furthermore, the CDF highlights that this estimate is incomplete, as it does not include the rebates and benefits provided by drug wholesalers, the volume of which is unknown.

The Federal Office of Public Health (OFSP) admits in the audit that it possesses no data on these wholesaler benefits. This lack of information is a central criticism of the report, indicating a systemic issue where the Confederation does not fully grasp the extent or forms of these financial advantages circulating within the healthcare system.